Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | OTC | P00480 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.37 |
| ▸ | NPY4R | P50391 | 6/20 | 0.37 |
| ▸ | NPY1R | P25929 | 5/20 | 0.37 |
| ▸ | NPY2R | P49146 | 4/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | RRM1 | P23921 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884383 | 1.00 | DPP7 (0.40) | DPP7OTCALOX15MEN1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL1897055 | 0.98 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL9189053 | 0.98 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 | |
| SCHEMBL23100143 | 0.98 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 | |
| Water SCHEMBL10483772 | 0.98 | DPP7 (0.39) | DPP7OTCALOX15MEN1CYP1A2 | |
| Arginine SCHEMBL21592227 | 0.87 | OTC (0.53) | OTCALOX15MEN1CYP1A2KMT2A | |
| SCHEMBL15169368 | 0.85 | DPP7 (0.42) | DPP7OTCCYP1A2DDAH1GNAI3 | |
| SCHEMBL30256813 | 0.85 | DPP7 (0.42) | DPP7OTCALOX15MEN1CYP1A2 | |
| SCHEMBL598710 | 0.85 | DPP7 (0.42) | DPP7OTCALOX15MEN1CYP1A2 | |
| SCHEMBL304115 | 0.85 | DPP7 (0.42) | DPP7OTCALOX15MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| CN-120054626-A | Solid Lewis acid catalyst and preparation method and application thereof | 四川大学 | 2025-05-30 | — | — | CN | claimed |
| EP-3547995-B1 | COMPOSITION FOR PROVIDING HIGH LIFT AND COLOR DEPOSIT | HENKEL AG & CO KGAA (DE) | 2024-08-14 | — | — | EP | claimed |
| EP-4104859-B1 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF | GENENTECH INC (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4108259-B1 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF | GENENTECH INC (US) | 2024-01-03 | — | — | EP | claimed |
| US-11767370-B2 | Process for concentration of antibodies and therapeutic products thereof | GENENTECH, INC. (US) | 2023-09-26 | — | — | US | claimed |
| CN-116496026-A | Composite material for improving reinforcement and carbonization resistance of alkali-activated cementing material and preparation method thereof | 东南大学 | 2023-07-28 | — | — | CN | claimed |
| US-20230074486-A1 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF | GENENTECH, INC. (US) | 2023-03-09 | — | — | US | claimed |
| EP-4108259-A1 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF | Genentech, Inc. (US) | 2022-12-28 | — | — | EP | claimed |
| EP-4104859-A1 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF | Genentech, Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| US-20040220160-A1 | Topical testosterone formulations and associated methods | KRYGER ABRAHAM H (US) | 2004-11-04 | — | — | US | claimed |
| US-6743448-B2 | FINENESS PARTICLE SIZE; HORMONE REPLACEMENT THERAPY | KRYGER ABRAHAM H (US) | 2004-06-01 | — | — | US | claimed |
| WO-2002055020-A9 | TOPICAL TESTOSTERONE FORMULATIONS AND ASSOCIATED METHODS | TESTOCREME LLC (US) | 2003-11-06 | — | — | WO | claimed |
| US-20020150625-A1 | Topical testosterone formulations and associated methods | KRYGER ABRAHAM H (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002055020-A2 | TOPICAL TESTOSTERONE FORMULATIONS AND ASSOCIATED METHODS | TESTOCREME LLC (US) | 2002-07-18 | — | — | WO | claimed |
| EP-0674525-B1 | AQUEOUS PHARMACEUTICAL PREPARATIONS OF G-CSF WITH A LONG SHELF LIFE | ROCHE DIAGNOSTICS GMBH (DE) | 2001-07-25 | — | — | EP | claimed |
| US-5919443-A | GRANULOCYTE COLONY STIMULATING FACTOR | BOEHRINGER MANHEIM GMBH (DE) | 1999-07-06 | — | — | US | claimed |
| US-5919757-A | GRANULOCYTE COLONY STIMULATING FACTOR MIXTURE CONTAININGBUFFER AND SURFACTANT | BOEHRINGER MANNHEIM GMBH (DE) | 1999-07-06 | — | — | US | claimed |
| EP-0674524-B1 | STABLE LYOPHILIZED PHARMACEUTICAL PREPARATIONS G-CSF | BOEHRINGER MANNHEIM GMBH (DE) | 1998-04-15 | — | — | EP | claimed |
| US-3997659-A | PEROXIDE AND PEROXYDISULFATE OR PEROXYDIPHOSPHATE | THE PROCTER & GAMBLE COMPANY (US) | 1976-12-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | DPP7 1167/4885OTC 3847/4885ALOX15 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.